A study published in the Journal of Vascular and Interventional Radiology looked at the long-term survival benefits from radiofrequency ablation (RFA) in patients with localised renal cell carcinoma (RCC).
The outcomes of 100 patients with localised RCC (kidney cancer that has not spread) were looked at retrospectively. All patients had percutaneous radiofrequency ablation and were followed for a median of 62.8 months. 10-year overall cancer-specific survival was 86% and progression-free survival was 92%.
The authors highlight that the data from this study were from a single hospital, and there was an obvious patient selection bias. However, patients should be reassured that percutaneous radiofrequency ablation of renal masses can be a safe and effective treatment.